Akero Therapeutics, Inc. (NASDAQ:AKRO) CEO Andrew Cheng Sells 63,539 Shares

Akero Therapeutics, Inc. (NASDAQ:AKRO) CEO Andrew Cheng sold 63,539 shares of the firm’s stock in a transaction dated Friday, October 18th. The stock was sold at an average price of $31.53, for a total value of $2,003,384.67. Following the transaction, the chief executive officer now owns 605,417 shares of the company’s stock, valued at $19,088,798.01. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Andrew Cheng also recently made the following trade(s):

• On Wednesday, October 16th, Andrew Cheng sold 24,992 shares of Akero Therapeutics stock. The stock was sold at an average price of $31.14, for a total value of $778,250.88.
• On Tuesday, September 10th, Andrew Cheng sold 1,738 shares of Akero Therapeutics stock. The stock was sold at an average price of $26.18, for a total value of $45,500.84.

Akero Therapeutics Trading Up 1.3 %

AKRO stock traded up $0.41 during mid-day trading on Friday, reaching $31.23. The company’s stock had a trading volume of 484,151 shares, compared to its average volume of 892,003. The company has a current ratio of 24.89, a quick ratio of 24.89 and a debt-to-equity ratio of 0.04. Akero Therapeutics, Inc. has a 12 month low of $11.25 and a 12 month high of $37.00. The business’s 50 day moving average price is $27.36 and its 200 day moving average price is $24.24. The company has a market cap of $2.16 billion, a price-to-earnings ratio of -9.76 and a beta of -0.25.

Akero Therapeutics (NASDAQ:AKRO) last announced its quarterly earnings data on Friday, August 9th. The company reported ($0.81) EPS for the quarter, beating analysts’ consensus estimates of ($0.90) by $0.09. On average, equities research analysts predict that Akero Therapeutics, Inc. will post -3.64 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Akero Therapeutics in a report on Thursday, June 20th. HC Wainwright reiterated a “buy” rating and issued a $50.00 target price on shares of Akero Therapeutics in a report on Tuesday, September 17th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $43.20.

Institutional Investors Weigh In On Akero Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the company. Rheos Capital Works Inc. grew its stake in Akero Therapeutics by 27.8% in the third quarter. Rheos Capital Works Inc. now owns 276,000 shares of the company’s stock valued at $7,918,000 after acquiring an additional 60,000 shares during the period. Creative Planning purchased a new position in shares of Akero Therapeutics during the third quarter valued at approximately $371,000. Handelsbanken Fonder AB boosted its position in shares of Akero Therapeutics by 12.4% during the third quarter. Handelsbanken Fonder AB now owns 20,000 shares of the company’s stock valued at $574,000 after buying an additional 2,200 shares during the last quarter. Perceptive Advisors LLC boosted its position in shares of Akero Therapeutics by 8.1% during the second quarter. Perceptive Advisors LLC now owns 1,499,897 shares of the company’s stock valued at $35,188,000 after buying an additional 112,426 shares during the last quarter. Finally, Long Focus Capital Management LLC boosted its position in shares of Akero Therapeutics by 119.0% during the second quarter. Long Focus Capital Management LLC now owns 719,604 shares of the company’s stock valued at $16,882,000 after buying an additional 391,000 shares during the last quarter.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.